Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy
Official title: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
Funded at Athna Biotech, INC. · NIH-11314266 · Data updated 2026-11-12
A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Athna Biotech, INC. NIH-funded |
| Lab location | 1 site (Athens, UNITED STATES) |
| Project start | May 5, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $937,492 |
| NIH project number | 2R42CA262399-02 |
| Project ID | NIH-11314266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with non-muscle invasive bladder cancer who have not adequately responded to or cannot tolerate BCG therapy.
✕Less likely to help
Patients with cancers beyond NMIBC or those who do not have access to intravesical treatment may not benefit.
What this research studies
This grant supports developing AB-002, a salt-based nanomedicine that is put directly into the bladder to attack cancer cells while sparing healthy tissue. The approach uses tiny, lipid-coated salt nanoparticles that release ions inside cancer cells to trigger their destruction and also stimulate an immune response against the tumor. Researchers will study how well this intravesical therapy works against NMIBC and how it prompts lasting anti-tumor immunity. If successful, it could offer a bladder-sparing option for patients who do not respond to or cannot tolerate BCG. The project spans several years to evaluate safety, effectiveness, and immune effects in a clinical context.
Why it matters
Potential benefit: If successful, this therapy could provide a bladder-preserving treatment option for BCG-unresponsive NMIBC, potentially reducing the need for cystectomy.
How similar studies have gone: Preclinical and early clinical studies of bladder-directed nanomedicines have shown potential, but this exact salt-based approach is novel and promising but not yet proven.
Where this research is happening
-
Athna Biotech, INC.
Athens, United States Active
Researchers
- Principal investigator: Xie, Jin — Athna Biotech, INC.
- Study coordinator: Xie, Jin
Related research
Other NIH-funded projects on the same topics.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
-
Body fats and immune signals shaping bladder cancer outlook
This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.
-
Novel combination immunotherapy for non–muscle-invasive bladder cancer
Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.
-
Why some bladder cancers don't respond to BCG treatment
This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.
-
HLA‑E/NKG2A immune 'brake' in early bladder cancer
The team is exploring whether targeting an immune 'brake' called HLA‑E/NKG2A can help people with non‑muscle‑invasive (early) bladder cancer who receive BCG therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.